Optimizing adjuvant endocrine therapy for postmenopausal breast cancer: the modified CYP2D6 genotype-based modeling analyses

被引：0
|
作者：
Di, G. H. [1 ]
Shao, Z. M. [1 ]
Yu, K. D. [1 ]
机构：
[1] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70445-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [21] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Jin, Y
    Desta, Z
    Stearns, V
    Ward, B
    Ho, H
    Lee, KH
    Skaar, T
    Storniolo, AM
    Li, L
    Araba, A
    Blanchard, R
    Nguyen, A
    Ullmer, L
    Hayden, J
    Lemler, S
    Weinshilboum, RM
    Rae, JM
    Hayes, DF
    Flockhart, DA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 30 - 39
  • [22] CYP2D6 GENOTYPE FREQUENCIES IN BREAST-CANCER PATIENTS
    BUCHERT, E
    WOOSLEY, RL
    OLIVER, S
    SWAIN, S
    RIEGEL, AT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 214 - 214
  • [23] Endocrine Therapy: Translational Research on CYP2D6 Genetics for Tamoxifen Response in Breast Cancer
    Branch, H.
    Schroth, W.
    Bacchus, L.
    Simon, W.
    Eichelbaum, M.
    Schwab, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (12) : 1223 - 1224
  • [24] CYP2D6 genotype and tamoxifen response in pre and postmenopausal Thai women with hormone responsive breast cancer
    Noonpakdee, W.
    Chamnanphon, M.
    Sukasem, C.
    Chantratita, W.
    Pasomsub, E.
    FEBS JOURNAL, 2013, 280 : 311 - 312
  • [25] CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
    Regan, Meredith M.
    Leyland-Jones, Brian
    Bouzyk, Mark
    Pagani, Olivia
    Tang, Weining
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thuerlimann, Beat
    Lyng, Maria B.
    Ditzel, Henrik J.
    Neven, Patrick
    Debled, Marc
    Maibach, Rudolf
    Price, Karen N.
    Gelber, Richard D.
    Coates, Alan S.
    Goldhirsch, Aron
    Rae, James M.
    Viale, Giuseppe
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06): : 441 - 451
  • [26] The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population
    Lan, Bo
    Ma, Fei
    Zhai, Xiaoyu
    Li, Qiao
    Chen, Shanshan
    Wang, Jiayu
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 184 - 189
  • [27] Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes
    Li, Xin
    Li, Zehao
    Li, Lin
    Liu, Tong
    Qian, Cheng
    Ren, Yanlv
    Li, Zhigao
    Chen, Kejin
    Ji, Dongchen
    Zhang, Ming
    Wang, Jinsong
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 134 - 142
  • [28] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
    Madlensky, L.
    Natarajan, L.
    Tchu, S.
    Pu, M.
    Mortimer, J.
    Flatt, S. W.
    Nikoloff, D. M.
    Hillman, G.
    Fontecha, M. R.
    Lawrence, H. J.
    Parker, B. A.
    Wu, A. H. B.
    Pierce, J. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
  • [29] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    T. Ramón y Cajal
    A. Altés
    L. Paré
    E. del Rio
    C. Alonso
    A. Barnadas
    M. Baiget
    Breast Cancer Research and Treatment, 2010, 119 : 33 - 38
  • [30] Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
    Ramon y Cajal, T.
    Altes, A.
    Pare, L.
    del Rio, E.
    Alonso, C.
    Barnadas, A.
    Baiget, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 33 - 38
12345